Antimicrobial therapy for sepsis and multiorgan failure;Antibiotika bei sepsis und multiorganversagen

Intensivmedizin und Notfallmedizin

Volumn 43, Issue 2, 2006, Pages 94-102

  Muller E ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antimicrobial therapy; Nosocomial infection; Pneumonia; Sepsis

Indexed keywords

AMINOPENICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; LINEZOLID; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; BACTEREMIA; CATHETER INFECTION; CLINICAL FEATURE; CRITICAL ILLNESS; DEVICE INFECTION; DISEASE SEVERITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; EPIDEMIOLOGICAL DATA; HOSPITAL CARE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; MEDICAL INFORMATION; MICROBIOLOGY; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PATIENT CARE; PNEUMONIA; REVIEW; RISK FACTOR; SEPSIS; SURGICAL INFECTION; SURVIVAL; TREATMENT PLANNING; URINARY TRACT INFECTION;

EID: 33645068201     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-006-0592-6     Document Type: Review

References (72)

1. Sandiumenge A, Diaz E, Bodi M, Rello J (2003) Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 29(6):876-883
2. Burke JP (2003) Infection control - a problem for patient safety. N Engl J Med 348(7):651-656
3. Vincent JL, Bihari DJ, Suter PM et al (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Jama 274(8):639-644
4. Alberti C, Brun-Buisson C, Burchardi H et al (2002) Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28(2):108-121
5. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I (2003) The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 29(9):1464-1471
6. Kollef MH (2004) Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 32(6):1396-1405
7. Fagon JY (2002) Prevention of ventilator-associated pneumonia. Intensive Care Med 28(7):822-823
8. Kollef MH (1999) The prevention of ventilator-associated pneumonia. N Engl J Med 340(8):627-634
9. Rello J, Diaz E (2003) Pneumonia in the intensive care unit. Crit Care Med 31(10):2544-2551
10. Rello J, Ollendorf DA, Oster G et al (2002) Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122(6):2115-2121
11. Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340(3):207-214
12. Fabregas N, Torres A, El-Ebiary M et al (1996) Histopathologic and microbiologic aspects of ventilator-associated pneumonia [see comments]. Anesthesiology 84(4):760-771
13. Gastmeier P (2004) Nosocomial infection surveillance and control policies. Curr Opin Infect Dis 17(4):295-301
14. Warren DK, Shukla SJ, Olsen MA et al (2003) Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 31(5):1312-1317
15. Bauer TT (2003) Nosocomial pneumonia: therapy is just not good enough. Chest 124(5):1632-1634
16. Girou E, Brun-Buisson C, Taille S, Lemaire F, Brochard L (2003) Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema. JAMA 290(22):2985-2991
17. Mehta S, Hill NS (2001) Noninvasive ventilation. Am J Respir Crit Care Med 163(2):540-577
18. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M (1999) Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 354(9193):1851-1858
19. Krüger WA, Lenhart FP, Neeser G et al (2002) Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 166(8):1029-1037
20. Kollef MH (2003) Selective digestive decontamination should not be routinely employed. Chest 123(Suppl 5):464S-468S
21. Berra L, Panigada M, De Marchi L et al (2003) New approaches for the prevention of airway infection in ventilated patients. Lessons learned from laboratory animal studies at the National Institutes of Health. Minerva Anestesiol 69(5):342-347
22. Berra L, De Marchi L, Yu ZX, Laquerriere P, Baccarelli A, Kolobow T (2004) Endotracheal tubes coated with antiseptics decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology 100(6):1446-1456
23. Marshall JC, Maier RV, Jimenez M, Dellinger EP (2004) Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32(Suppl 11):S513-S526
24. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118(1):146-155
25. Kollef M (2003) Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 63(20):2157-2168
26. Kollef MH (2003) Treatment of ventilator-associated pneumonia: get it right from the start. Crit Care Med 31(3):969-970
27. Kollef MH (2003) The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 115(7):582-584
28. Höffken G, Niederman MS (2002) Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122(6):2183-2196
29. Niederman MS (2003) Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 31(2):608-616
30. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH (2002) Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122(1):262-268
31. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36(11):1418-1423
32. Sandiumenge A, Diaz E, Bodi M, Rello J (2003) Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 29(6):876-883
33. Lorenz J, Bodmann KF, Bauer TT, Ewig S, Trautmann M, Vogel F (2003) Nosokomiale Pneumonie: Prävention, Diagnose, Therapie. Pneumologie 57(9):532-545
34. Kollef MH (2003) An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Clin Infect Dis 36(9):1119-1121
35. Trouillet JL, Chastre J, Vuagnat A et al (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157(2):531-539
36. Russell JA, Singer J, Bernard GR et al (2000) Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 28(10):3405-3411
37. Weber DJ, Raasch R, Rutala WA (1999) Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 115(Suppl 3):34S-41S
38. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160(2):608-613
39. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16): 1546-1554
40. Pappas PG, Rex JH, Lee J et al (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37(5):634-643
41. Ostrosky-Zeichner L, Rex JH, Pappas PG et al (2003) Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47(10):3149-3154
42. Pfaller MA, Messer SA, Boyken L et al (2004) In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 48(3):201-205
43. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr (2004) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38(12):1700-1705
44. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK (2004) Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 39(7):971-979
45. Karam GH, Niederman MS (2003) How do we achieve adequate therapy for severe infection? Crit Care Med 31(2):648-650
46. Iregui M, Kollef MH (2002) Prevention of ventilator-associated pneumonia: selecting interventions that make a difference. Chest 121(3):679-681
47. Ewig S, Torres A (2002) Prevention and management of ventilator- associated pneumonia. Curr Opin Crit Care 8(1):58-69
48. Brun-Buisson C (2003) Antibiotic therapy of ventilator-associated pneumonia: in search of the magic bullet. Chest 123(3):670-673
49. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30(3):388-394
50. Shorr AF, Susla GM, Kollef MH (2004) Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 32(1):137-143
51. Solomkin JS, Bjornson HS, Cainzos M et al (2004) A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am J Surg 187(1):134-145
52. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH (2003) Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 25(3):980-992
53. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124(5):1789-1797
54. Bochud PY, Bonten M, Marchetti O, Calandra T (2004) Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 32(Suppl 11):S495-S512
55. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Bmj 328(7441):668
56. Pappas PG, Rex JH, Sobel JD et al (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38(2):161-189
57. Kullberg BJ et al (2004) In: ECCMID, Prag, Mai 2004, Abstract 0245
58. Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020-2029
59. Fiaccadori E, Maggiore U, Rotelli C et al (2004) Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 32(12):2437-2442
60. Egerer G, Goldschmidt H, Salwender H et al (2000) Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents 15(2):119-123
61. Grant E, Nicolau DP, Nightingale CH, Quintiliani R (1999) Continuous infusion of beta-lactam antibiotics. Conn Med 63(5):275-277
62. Micek ST, Ward S, Fraser VJ, Kollef MH (2004) A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 125(5):1791-1799
63. Yu VL, Singh N (2004) Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med 30(5):735-738
64. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162(2 Pt 1):505-511
65. Luna CM, Blanzaco D, Niederman MS et al (2003) Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 31(3):676-682
66. Luyt CE, Chastre J, Fagon JY (2004) Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med 30(5):844-852
67. Micek ST, Shah RA, Kollef MH (2003) Management of severe sepsis: integration of multiple pharmacologic interventions. Pharmacotherapy 23(11):1486-1496
68. Chastre J, Wolff M, Fagon JY et al (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama 290(19):2588-2598
69. Bodi M, Ardanuy C, Olona M, Castander D, Diaz E, Rello J (2001) Therapy of ventilator-associated pneumonia: the Tarragona strategy. Clin Microbiol Infect 7(1):32-33
70. Hall CS, Ost DE (2003) Effectiveness of programs to decrease antimicrobial resistance in the intensive care unit. Semin Respir Infect 18(2):112-121
71. Mehta RM, Niederman MS (2003) Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med 18(4):175-188
72. Dellinger RP, Carlet JM, Masur H et al (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30(4):536-555